

Instruction Manual

Catalog Number	PK-AB718-3401P
Quantity	50 µg
Source	16 amino acids near the carboxy terminus of human IRF8
Formulation	Peptide is supplied as 200 µg/ml solution in PBS pH 7.2 (10 mM NaH ₂ PO ₄ , 10 mM Na ₂ HPO ₄ , 130 mM NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Reconstitution	During shipment, small volumes of antibody will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 µl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container's cap.
Storage & Stability	Store IRF8 peptide at -20°C, stable for one year.
Application	IRF8 peptide is used for blocking the activity of IRF8 antibody.
References	<p>Weisz A, Marx P, Sharf R, et al. The human interferon consensus sequence binding protein (H-ICSBP) is a negative regulator of enhancer elements common to interferon inducible genes. <i>J. Biol. Chem.</i> 1992; 267:25589-96.</p> <p>Heiser D, Labi V, Erlacher M, et al. The Bcl-2 protein family and its role in the development of neoplastic disease. <i>Exp. Gerontol.</i> 2004; 39:1125-35.</p> <p>Gonzalez-Garcia M, Perez-Ballestro R, Ding L et al. bcl-xL is the major bcl-x mRNA form expressed during murine development and its product localizes to mitochondria. <i>Development</i> 1994; 120:3033-42.</p> <p>Zhou XM, Liu Y, Payne G, et al. Growth factors inactivate the cell death promoter BAD by phosphorylation of its BH3 domain on Ser155. <i>J. Biol. Chem.</i> 2000; 275:25046-51.</p>

FOR IN VITRO RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC PROCEDURES.